QDEL shows dramatic financial distress with massive operating losses exceeding $900M despite some improvement from prior year's $2B loss, combined with a 36% decline in stockholders' equity and strategic business unit wind-downs.
The company remains in severe financial distress with operating losses approaching $1 billion annually, though showing improvement from catastrophic prior-year losses of $2 billion. The strategic decision to wind down the U.S. donor screening business (VIP platform and microplate assays) signals management is actively divesting underperforming segments, but this also indicates core business challenges that required portfolio rationalization.
While QDEL showed meaningful improvement with operating losses narrowing from $2.0B to $919M and stronger cash generation (operating cash flow up 27% to $105M), the overall financial picture remains deeply concerning. The company experienced a massive 36% decline in stockholders' equity to $1.9B alongside an 11.9% increase in total liabilities to $3.8B, indicating deteriorating capital structure. Despite improved cash position (+73% to $170M) and higher accounts receivable suggesting revenue growth, the persistent massive losses and eroding equity base signal ongoing fundamental business challenges that pose significant risks to long-term viability.
Cash position surged 72.7% — strong cash generation or capital raise providing significant financial cushion.
Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.
Receivables surged 47.7% — revenue recognized but not yet collected; watch for collection issues or channel stuffing.
Net income grew 44.8% — bottom-line growth signals improving overall business health.
Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.
Operating cash flow grew 26.7% — strong conversion of earnings to cash, healthy business fundamentals.
Current assets grew 18.7% — improving short-term liquidity or inventory/receivables build.
R&D spending cut 14.9% — could signal cost discipline or concerning reduction in innovation investment.
Liabilities increased 11.9% — monitor debt-to-equity ratio and interest coverage.
Total assets contracted 10.2% — asset sales, write-downs, or balance sheet optimization underway.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →